These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26323991)

  • 1. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.
    Liu Q; Liu Y; Li W; Wang X; Sawaya R; Lang FF; Yung WK; Chen K; Fuller GN; Zhang W
    Acta Neuropathol; 2015 Oct; 130(4):587-97. PubMed ID: 26323991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical characteristics and prognostic factors of multiple lesions in glioblastomas.
    Tunthanathip T; Sangkhathat S; Tanvejsilp P; Kanjanapradit K
    Clin Neurol Neurosurg; 2020 Aug; 195():105891. PubMed ID: 32480195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.
    Brosnan-Cashman JA; Davis CM; Diplas BH; Meeker AK; Rodriguez FJ; Heaphy CM
    Mod Pathol; 2021 Oct; 34(10):1810-1819. PubMed ID: 34103668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
    Carrillo JA; Lai A; Nghiemphu PL; Kim HJ; Phillips HS; Kharbanda S; Moftakhar P; Lalaezari S; Yong W; Ellingson BM; Cloughesy TF; Pope WB
    AJNR Am J Neuroradiol; 2012 Aug; 33(7):1349-55. PubMed ID: 22322613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.
    Chaurasia A; Park SH; Seo JW; Park CK
    J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of immunobiologic markers in primary and recurrent glioblastoma.
    Rahman M; Kresak J; Yang C; Huang J; Hiser W; Kubilis P; Mitchell D
    J Neurooncol; 2018 Apr; 137(2):249-257. PubMed ID: 29302887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased LGALS3 expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastoma.
    He X; Zhang S; Chen J; Li D
    Cancer Med; 2019 May; 8(5):2031-2040. PubMed ID: 30848102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.
    Song X; Andrew Allen R; Terence Dunn S; Fung KM; Farmer P; Gandhi S; Ranjan T; Demopoulos A; Symons M; Schulder M; Li JY
    Int J Clin Exp Pathol; 2011; 4(7):651-60. PubMed ID: 22076165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
    Sturm D; Witt H; Hovestadt V; Khuong-Quang DA; Jones DT; Konermann C; Pfaff E; Tönjes M; Sill M; Bender S; Kool M; Zapatka M; Becker N; Zucknick M; Hielscher T; Liu XY; Fontebasso AM; Ryzhova M; Albrecht S; Jacob K; Wolter M; Ebinger M; Schuhmann MU; van Meter T; Frühwald MC; Hauch H; Pekrun A; Radlwimmer B; Niehues T; von Komorowski G; Dürken M; Kulozik AE; Madden J; Donson A; Foreman NK; Drissi R; Fouladi M; Scheurlen W; von Deimling A; Monoranu C; Roggendorf W; Herold-Mende C; Unterberg A; Kramm CM; Felsberg J; Hartmann C; Wiestler B; Wick W; Milde T; Witt O; Lindroth AM; Schwartzentruber J; Faury D; Fleming A; Zakrzewska M; Liberski PP; Zakrzewski K; Hauser P; Garami M; Klekner A; Bognar L; Morrissy S; Cavalli F; Taylor MD; van Sluis P; Koster J; Versteeg R; Volckmann R; Mikkelsen T; Aldape K; Reifenberger G; Collins VP; Majewski J; Korshunov A; Lichter P; Plass C; Jabado N; Pfister SM
    Cancer Cell; 2012 Oct; 22(4):425-37. PubMed ID: 23079654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors.
    Paldor I; Pearce FC; Drummond KJ; Kaye AH
    J Clin Neurosci; 2016 Dec; 34():128-132. PubMed ID: 27593971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of IDH1 Mutation Status in Glioblastoma Using Machine Learning Technique Based on Quantitative Radiomic Data.
    Lee MH; Kim J; Kim ST; Shin HM; You HJ; Choi JW; Seol HJ; Nam DH; Lee JI; Kong DS
    World Neurosurg; 2019 May; 125():e688-e696. PubMed ID: 30735871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 Mutation and Extraneural Metastasis of Glioblastoma: Insights From an Institutional Experience and Comprehensive Literature Review.
    Zhang X; Katsakhyan L; LiVolsi VA; Roth JJ; Rassekh CH; Bagley SJ; Nasrallah MP
    Am J Surg Pathol; 2021 Nov; 45(11):1516-1526. PubMed ID: 34366423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional diversity of long-term glioblastoma survivors.
    Gerber NK; Goenka A; Turcan S; Reyngold M; Makarov V; Kannan K; Beal K; Omuro A; Yamada Y; Gutin P; Brennan CW; Huse JT; Chan TA
    Neuro Oncol; 2014 Sep; 16(9):1186-95. PubMed ID: 24662514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
    Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
    Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
    Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
    Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.